MINNEAPOLIS, April 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of cutting-edge life science tools, today announced an Early Access Program for its latest advancement in spatial biology: a powerful new assay for in situ detection of protein proximity. Built upon Advanced Cell Diagnostics RNAscope™ technology, this next-generation assay is designed to reveal functional interactions between proteins within intact tissues, delivering a spatial solution to explore how molecular signaling shapes disease processes — offering a truly integrated spatial multiomic view.
"This new protein proximity assay opens the door to seeing functional interactions between proteins and not merely their presence in a tissue," said Dr. Matt McManus, President of Bio-Techne's Diagnostics & Spatial Biology Segment. "It's a powerful step forward in understanding the dynamic interplay within tissues that drives biology and disease."
Conventional methods for studying molecular interactions in tissues that separately measure proteins and RNA risk losing spatial fidelity, while bulk proximity assays provide no localization data. Bio-Techne's proximity detection technology addresses these gaps with a clear visual signal at subcellular resolution, built to be compatible with the RNAscope™ Multiomic LS workflow on BOND RX. This capability is particularly valuable for research areas where context matters — such as assessing immune checkpoint dynamics, investigating bispecific antibodies and studying protein interactions at synaptic junctions.
The Early Access Program is available to select institutions and researchers interested in incorporating spatial protein proximity capabilities into their workflows. Proof-of-concept data and case studies will be shared at the 2025 American Association for Cancer Research (AACR) annual meeting, presented by Bio-Techne's scientific team.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com or follow the Company on social media at Facebook, LinkedIn, Twitter or YouTube.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
This email address is being protected from spambots. You need JavaScript enabled to view it.
612-656-4416
| Last Trade: | US$51.48 |
| Daily Change: | -1.66 -3.12 |
| Daily Volume: | 749,444 |
| Market Cap: | US$8.180B |
June 24, 2025 May 29, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
